Cargando…
Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab
We had the challenged to treat a 40-year-old female with Systemic Scleroderma who was showing unspecific symptoms. During her time at the hospital she rapidly develops renal dysfunction, associated with hypertension. She required renal replacement therapy initiation and we observed a decline in hemo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218791/ https://www.ncbi.nlm.nih.gov/pubmed/30425869 http://dx.doi.org/10.1155/2018/6051083 |
_version_ | 1783368530769477632 |
---|---|
author | Uriarte, Maite Hurtado Larrarte, Carolina Rey, Laura Bravo |
author_facet | Uriarte, Maite Hurtado Larrarte, Carolina Rey, Laura Bravo |
author_sort | Uriarte, Maite Hurtado |
collection | PubMed |
description | We had the challenged to treat a 40-year-old female with Systemic Scleroderma who was showing unspecific symptoms. During her time at the hospital she rapidly develops renal dysfunction, associated with hypertension. She required renal replacement therapy initiation and we observed a decline in hemoglobin and platelets numbers. We confirm a microangiopathic hemolytic anemia and rule out other immune diseases or thrombotic thrombocytopenic purpura. Systemic Sclerosis is a chronic immune disorder of unknown origin that it is not completely understood. It is believed that environmental factors may contribute and also altered genes may be implicated in the immune system's function. Microangiopathic hemolytic anemia occurs in 43% of patients who develop scleroderma renal crisis and an activation of the complement system through the classical pathway may be involved. Given that context we decided to treat the patients with C5 blocker Eculizumab and obtain an extraordinary positive response. |
format | Online Article Text |
id | pubmed-6218791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-62187912018-11-13 Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab Uriarte, Maite Hurtado Larrarte, Carolina Rey, Laura Bravo Case Rep Nephrol Case Report We had the challenged to treat a 40-year-old female with Systemic Scleroderma who was showing unspecific symptoms. During her time at the hospital she rapidly develops renal dysfunction, associated with hypertension. She required renal replacement therapy initiation and we observed a decline in hemoglobin and platelets numbers. We confirm a microangiopathic hemolytic anemia and rule out other immune diseases or thrombotic thrombocytopenic purpura. Systemic Sclerosis is a chronic immune disorder of unknown origin that it is not completely understood. It is believed that environmental factors may contribute and also altered genes may be implicated in the immune system's function. Microangiopathic hemolytic anemia occurs in 43% of patients who develop scleroderma renal crisis and an activation of the complement system through the classical pathway may be involved. Given that context we decided to treat the patients with C5 blocker Eculizumab and obtain an extraordinary positive response. Hindawi 2018-10-23 /pmc/articles/PMC6218791/ /pubmed/30425869 http://dx.doi.org/10.1155/2018/6051083 Text en Copyright © 2018 Maite Hurtado Uriarte et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Uriarte, Maite Hurtado Larrarte, Carolina Rey, Laura Bravo Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab |
title | Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab |
title_full | Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab |
title_fullStr | Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab |
title_full_unstemmed | Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab |
title_short | Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab |
title_sort | scleroderma renal crisis debute with thrombotic microangiopathy: a successful case treated with eculizumab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218791/ https://www.ncbi.nlm.nih.gov/pubmed/30425869 http://dx.doi.org/10.1155/2018/6051083 |
work_keys_str_mv | AT uriartemaitehurtado sclerodermarenalcrisisdebutewiththromboticmicroangiopathyasuccessfulcasetreatedwitheculizumab AT larrartecarolina sclerodermarenalcrisisdebutewiththromboticmicroangiopathyasuccessfulcasetreatedwitheculizumab AT reylaurabravo sclerodermarenalcrisisdebutewiththromboticmicroangiopathyasuccessfulcasetreatedwitheculizumab |